Ipsen’s ultra-rare bone disease drug flops in Phase II trial
Ipsen’s fidrisertib has failed to show meaningful benefit above placebo in a Phase II trial in patients with fibrodysplasia ossificans…
Musculoskeletal Disorders
-
-
PepGen’s stock up 120% on DM1 trial success
PepGen’s stock has risen by more than 120% after its investigational myotonic dystrophy type 1 (DM1) candidate reported the highest…
-
Alfasigma sets stage for Jyseleca in axSpA after Phase III win
Alfasigma plans to engage with regulators to seek approval for Jyseleca (filgotinib) in active axial spondyloarthritis (axSpA) following a successful…
-
Capricor touts long-term efficacy of DMD therapy ahead of FDA application
Capricor Therapeutics has released more positive three-year safety and efficacy data from the Phase II HOPE-2 open-label extension (OLE) trial…
-
FDA lifts clinical hold on Avidity’s lead antibody conjugate therapy trial
The US Food and Drug Administration (FDA) has lifted the partial clinical hold on Avidity Biosciences’ investigational drug, delpacibart etedesiran…
-
Spine BioPharma concludes enrolment in Phase III back pain treatment trial
Spine BioPharma has concluded subject enrolment in its Phase III MODEL clinical trial of SB-01 For Injection, aimed at treating…
-
Satellos Bioscience doses first subject in Phase I trial of SAT-3247
Satellos Bioscience has dosed the first subject in a Phase I clinical trial of SAT-3247, a potential treatment for Duchenne…
-
Immunis to use MRI-based AI muscle analysis for sarcopenia trial
Immunis has enlisted the services of Springbok Analytics in its Phase I/II clinical trial for a sarcopenia therapy, leveraging the…
-
FDA grants approval to DiscGenics for Phase III trial of cell therapy
The US Food and Drug Administration (FDA) has granted approval to DiscGenics for a Phase III clinical trial of its…
-
Swing publishes Phase III data for fibromyalgia digital therapy
Swing Therapeutics has published positive results from the Phase III trial of its digital therapeutic, Stanza, for the treatment of…
